CAR T-Cell Therapy Opportunity within Follicular Lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Follicular lymphoma (FL) is the second most commonly diagnosed, typically affecting individuals around 65 at presentation. Approximately 80% of patients with FL have a chromosomal abnormality known as t(14;18), which leads to the overexpression of the B-cell lymphoma 2 (BCL-2) protein. Most patients with low-grade FL (grade 1, 2, or 3A) are diagnosed at an advanced disease stage. However, treatment may not be necessary unless patients develop symptoms, organ function impairment, or symptomatic cytopenias. When treatment is required for patients with advanced-stage FL, several chemoimmunotherapeutic combinations can be used, including rituximab or obinutuzumab with cyclophosphamide, vincristine, and prednisone (CVP); rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP-R); or bendamustine plus rituximab (BR) or obinutuzumab, which have shown non-inferiority to conventional chemoimmunotherapy regimens. Another option is the combination of lenalidomide and rituximab. Patients who experience disease progression early (within 24 months) after initial first-line treatment containing anti-CD20 monoclonal antibody (POD24) tend to have poor outcomes. The treatment choice for patients with relapsed or refractory (R/R) FL depends on the aggressiveness and clinical presentation of the disease, along with the patient's performance status and existing comorbidities. Second-line and beyond treatment options include chemoimmunotherapy, radioimmunotherapy, phosphoinositide 3-kinase inhibitors (PI3Kis), tazemetostat (an inhibitor of enhancer of zeste homolog 2 - EZH2), and in some cases, autologous (auto-HCT) or allogeneic (allo-HCT) hematopoietic cell transplant. The prognosis for patients with R/R FL is generally poor, with expected short progression-free and overall survival. In the United States, two CD19-directed chimeric antigen receptor T-cell (CAR T) therapies, namely, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel, are approved for treating R/R FL. Tisagenlecleucel was granted accelerated approval by the FDA in May 2022 for treating adults with R/R FL after failing two or more lines of systemic therapy.

Thelansis’s “CAR T-Cell Therapy Opportunity within Follicular Lymphoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential CAR T-Cell Therapy Opportunity within Follicular Lymphoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of CAR T-Cell Therapy Opportunity within Follicular Lymphoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

CAR T-Cell Therapy Opportunity within Follicular Lymphoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: CAR T-Cell Therapy Opportunity within Follicular Lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033